Table 1.
Effects of MEPI expression on tumor size, tumor incidence, lymph node status, and lung metastasis of MDA-MB-435 cells
| Treatment group | Tumor vol of primary size, mm3 | Tumor incidence tumor/total (%) | Lymph node positive/total (%) | Lung metastasis positive/total (%) |
|---|---|---|---|---|
| MDA-MB-435 | 1589 ± 368 | 15/16 (100) | 7/16 (44) | 2/8 (25) |
| Neo-435-2 | 1295 ± 275 | 15/16 (94) | 9/16 (56) | 3/8 (38) |
| Neo-435-4 | 1745 ± 401 | 16/16 (100) | 8/15 (53) | 4/8 (50) |
| MEPI-435-1 | 478 ± 145 | 13/16 (81) | 3/15 (20) | 1/8 (13) |
| MEPI-435-10 | 271 ± 75 | 4/16 (25) | 1/16 (6) | 0/8 (0) |
On day 1, 300,000 cells were injected with MEPI into the mammary fat pads, and tumor volumes, lymph node and lung metastasis were determined as described in Materials and Methods. Volumes are expressed as mean ± SE (number of tumors assayed). There were 16 total injections for eight mice in each group, and each mouse received 2 injections. The mice were sacrificed 35 days after injection. Statistical comparisons for pooled MEPI-positive clones relative to pooled MEPI-negative clones indicated P < 0.001 for the mean tumor sizes and P < 0.01 for the lymph node and lung metastasis. Statistical comparison for primary tumors was analyzed by Student’s t test. A χ2 test was used for statistical analysis of lymph node and lung metastasis.